Figure 8A shows that CAF64-ORF-SFCM inhibited the epithelial-to-mesenchymal transition (EMT) process in MCF-7-breast cancer cells via upregulation of the epithelial markers (E-cadherin and EpCAM) and downregulation of the mesenchymal markers (vimentin and Snail) as compared to controls. This effect on the EMT markers was confirmed at the mRNA level of the CDH1 and CDH2 genes. Indeed, the CDH1 mRNA level was increased 1.8-fold, while the mRNA level of the mesenchymal marker CDH2 was reduced 2.5-fold in the MCF-7 cells treated with SFCM from CAF64-ORF cells relative to the controls (Figure 8B). The gene discussed is CDH2; the disease is breast cancer.